Our previous studies have shown that low expression of LASS2 is associated with poor prognosis in patients with breast cancer10, and deletion of LASS2 is associated with a high risk of spontaneous or DEN-induced HCC in hepatocyte-specific LASS2-KO mice models13, 14. Here, CERS2 is linked to hepatocellular carcinoma.